Cardio Diagnostics Holdings (CDIO) Free Cash Flow (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Free Cash Flow of -$1.6 million for Q1 2026, down 14.84% sequentially from -$1.4 million in Q4 2025, and down 11.24% YoY from -$1.8 million in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Free Cash Flow (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Free Cash Flow for 6 years, with the latest figure at -$1.6 million in Q1 2026.
- Quarterly Free Cash Flow fell 11.24% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.1 million (down 13.27% YoY) and the FY2025 annual result came in at -$5.9 million, down 13.56% from the prior year.
- Free Cash Flow slipped to -$1.6 million in Q1 2026 per CDIO's latest filing, from -$1.4 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$186090.0 in Q1 2022 and troughed at -$3.3 million in Q4 2022.
- A 5-year average of -$1.4 million and a median of -$1.4 million in 2022 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2024: Free Cash Flow tumbled 798659.2% in 2022, then jumped 37.2% in 2024.
- Over 5 years, Free Cash Flow stood at -$3.3 million in 2022, then soared by 32.83% to -$2.2 million in 2023, then surged by 37.2% to -$1.4 million in 2024, then grew by 2.44% to -$1.4 million in 2025, then slipped by 14.84% to -$1.6 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$1.6 million, -$1.4 million, and -$1.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Cardio Diagnostics Holdings | 6.05 Mn | 460,682.10 | - | -1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.34 Mn |
| Jun 30, 2026 | -1.34 Mn |
| Mar 31, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.56 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Dec 31, 2025 | -1.36 Mn |
| Sep 30, 2025 | -1.56 Mn |
| Sep 30, 2025 | -1.56 Mn |
| Jun 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | -1.59 Mn |
| Mar 31, 2025 | -1.41 Mn |
| Mar 31, 2025 | -1.41 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Sep 30, 2024 | -1.18 Mn |
| Sep 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Jun 30, 2024 | -1.38 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.25 Mn |